Aptose Biosciences
San Diego, California, United States · Biotechnology, Health Care, Medical
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 35
- Industries
- Biotechnology, Health Care, Medical
- Website
- aptosebiosciences.net
- Company page
Recent activity at Aptose Biosciences
- : SEC 8-K (5.02): On December 6, 2025, Aptose Biosciences Inc. announced a significant change in its management through a press release. The filing indicates that there was a departure of a certain officer, though the specific details regarding the individual and the terms of their departure were not disclosed in the 8-K. This change in management is poised to impact the strategic direction of the company moving forward. The announcement is part of the company’s ongoing efforts to align its leadership with current business objectives, though any financial implications have not been detailed.
- : Aptose Biosciences and Hanmi Pharmaceutical Extend Loan Agreement for US$11.9 Million to Develop Tuspetinib for AML Treatment.
- : Aptose Signs Debt Conversion Agreement with Hanmi
- : Aptose Biosciences Inc. publishes significant preclinical data on tuspetinib, a new therapy for acute myeloid leukemia.
- : Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS
- : Aptose Receives $10 Million Facility Agreement Loan and Negotiates Future Collaboration Agreement with Hanmi for Tuspetinib Development
- : Aptose Biosciences Inc. secured $4.43 million in funding through a registered direct offering for working capital and general corporate use.
- : Aptose Announces Closing Of $3 Million Investment By Hanmi Pharmaceutical
Aptose Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2024 | Seed | $4.4M |
| Sep 2023 | Seed | $3.0M |
Leadership
- William G. Rice, President
- Alex Chang, Director
- Fletcher Payne, Chief Financial Officer
Verified email and direct lines for Aptose Biosciences’s decision-makers are on Fundz. See plans
Employee benefit plans
Aptose Biosciences files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Aptose Biosciences
- Swarm Oncology Ltd · Biotechnology, Health Care, Medical, research, Therapeutics
- Onward Therapeutics SA · Biotechnology, Health Care, Medical, research, Therapeutics
- Celldex · Biotechnology, Health Care, Medical, research, Therapeutics
- Genentech · Biotechnology, Health Care, Medical, research, Therapeutics
- Corner Therapeutics · Biotechnology, Health Care, research, Therapeutics
About Aptose Biosciences: questions and answers
What does Aptose Biosciences do?
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.
Where is Aptose Biosciences headquartered?
Aptose Biosciences is headquartered in San Diego, California, United States.
How many employees does Aptose Biosciences have?
Aptose Biosciences has about 35 employees.
Has Aptose Biosciences raised funding?
Yes. Fundz has recorded 2 funding events for Aptose Biosciences. The most recent, Seed of $4.4M, was in Jun 2024.
Who leads Aptose Biosciences?
William G. Rice is a President at Aptose Biosciences.
What is the latest news on Aptose Biosciences?
On Dec 06, 2025, SEC 8-K (5.02): On December 6, 2025, Aptose Biosciences Inc. announced a significant change in its management through a press release. The filing indicates that there was a departure of a certain officer, though the specific details regarding the individual and the terms of their departure were not
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy